A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice
- 5.8k Downloads
Recent development in the field of COPD has focused on strategies aimed at reducing the underlying inflammation through selective inhibition of the phosphodiesterase type IV (PDE4) isoform. Although the anti-inflammatory and bronchodilator activity of selective PDE4 inhibitors has been well documented, their low therapeutic ratio and dose-dependent systemic side effects have limited their clinical utility. This study examined the effect of 2'-deoxy-2'-Fluoro-β-D-Arabinonucleic Acid (FANA)-containing antisense oligonucleotides (AON) targeting the mRNA for the PDE4B/4D and 7A subtypes on lung inflammatory markers, both in vitro and in vivo.
Normal human bronchial epithelial (NHBE) cells were transfected with FANA AON against PDE4B/4D and 7A alone or in combination. mRNA levels for target PDE subtypes, as well as secretion of pro-inflammatory chemokines were then measured following cell stimulation. Mice were treated with combined PDE4B/4D and 7A AON via endo-tracheal delivery, or with roflumilast via oral delivery, and exposed to cigarette smoke for one week. Target mRNA inhibition, as well as influx of inflammatory cells and mediators were measured in lung lavages. A two-week smoke exposure protocol was also used to test the longer term potency of PDE4B/4D and 7A AONs.
In NHBE cells, PDE4B/4D and 7A AONs dose-dependently and specifically inhibited expression of their respective target mRNA. When used in combination, PDE4B/4D and 7A AONs significantly abrogated the cytokine-induced secretion of IL-8 and MCP-1 to near baseline levels. In mice treated with combined PDE4B/4D and 7A AONs and exposed to cigarette smoke, significant protection against the smoke-induced recruitment of neutrophils and production of KC and pro-MMP-9 was obtained, which was correlated with inhibition of target mRNA in cells from lung lavages. In this model, PDE AONs exerted more potent and broader anti-inflammatory effects against smoke-induced lung inflammation than roflumilast. Moreover, the protective effect of PDE4B/4D and 7A AON was maintained when a once-weekly treatment schedule was used.
These results indicate that inhaled AON against PDE4B/4D and 7A have unique effects on biomarkers that are believed to be important in the pathophysiology of COPD, which supports further development as a potential therapy in this disease.
KeywordsChronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease Patient Smoke Exposure PDE4 Inhibitor Rolipram
Chronic obstructive pulmonary disease (COPD) is a complex syndrome characterized by chronic bronchitis, persistent cellular inflammation and progressive deterioration of airways and emphysema [1, 2, 3], for which cigarette smoking is by far the most important risk factor . COPD is one of the leading causes of death and morbidity worldwide . To date, no therapies have been shown to reduce mortality or prevent disease progression.
Although the composition of the lung cellular infiltrate varies among COPD patients, it is mainly constituted by neutrophils, macrophages and CD8+ T cells . The neutrophilic arm of airway inflammation is believed to be at the forefront of the lung pathogenesis in COPD patients [1, 7, 8, 9]. In the airways, neutrophils can release a number of mediators including oxygen radicals, elastases and metalloproteases (MMP) that contribute to self-perpetuation of inflammation and promote matrix breakdown, leading to alveolar destruction and emphysema [10, 11, 12]. Patients with COPD have an increased number of neutrophils in broncho-alveolar lavages (BAL), sputum, airways and lung parenchyma [8, 9], which directly correlates with disease severity . Their recruitment and accumulation in the airways is driven by chemokines such as interleukin-8 (IL-8), the levels of which have been found to be increased in sputum, alveolar macrophages and bronchial epithelium obtained from COPD patients [14, 15, 16].
In airways, elevation of intracellular cAMP has been associated with the general suppression of activity of inflammatory cells and relaxation of airway and vascular smooth muscle . Levels of intracellular cAMP are determined by the enzymatic balance between synthesis by adenylate cyclase and hydrolysis by phosphodiesterases (PDE). The PDEs represent a large family of isozymes , of which PDE4B and PDE4D isotypes are predominantly expressed in a variety of inflammatory and structural lung cells , and have been shown to modulate the inflammatory response [19, 20]. Small molecule PDE4 inhibitors with broad spectrum anti-inflammatory effects have been shown to reduce inflammatory cell recruitment and improve lung function in animal models of COPD [21, 22, 23]. Orally active PDE4 inhibitors such as cilomilast and roflumilast have reached an advanced clinical stage [24, 25, 26]. However one major hurdle in their development has been overcoming the dose-limiting systemic side effects, of which headaches, nausea and vomiting are the most common manifestations . Moreover, arteritis and vasculitis in the gastrointestinal tract and mesenteric blood vessels of rodents  and cardiac tissue of primates  have also raised a concern about their safety profile. Although delivery of PDE4 inhibitors via inhalation could represent an alternative approach [22, 30], the efficacy and safety of inhaled small molecules PDE4 inhibitors remains to be demonstrated [31, 32]. Consequently, improving the therapeutic ratio of PDE4 inhibitors still represents an important challenge.
One strategy to overcome these limitations is to develop more selective PDE4 inhibitors. For example, as systemic PDE4D inhibition appears to be responsible for the emetic effect , PDE4B-specific inhibitors might provide better therapeutic ratios. However, as PDE4D also has a predominant role in the activation of T cells , PDE4B-specific inhibitors might display reduced efficacy as compared to inhibitors targeting both isoforms in the lung. Another interesting approach would be to develop inhibitors of other PDE classes to be used in combination with PDE4 inhibitors, with the goal of maintaining or enhancing efficacy while reducing the dose-limiting side effects associated with these drugs . In this regard, PDE7 might represent a good candidate, as it is widely expressed in lung tissue and inflammatory cells . Moreover, in vitro studies have shown that the anti-inflammatory activity of the PDE4 inhibitor rolipram was enhanced by a PDE7 inhibitor, although the PDE7 inhibitor alone was without effect .
Antisense oligonucleotides (AON), by their ability to downregulate the expression of specific proteins, represent an innovative therapeutic strategy for lung diseases [38, 39, 40]. AONs can inhibit gene expression through formation of duplexes with complementary mRNA, activation of RNAseH and degradation of the duplexes or blockade of the translation machinery [41, 42, 43]. The lung is lined with surfactant, which is believed to facilitate AON uptake into cells following inhalation, without the need for specific carriers . Moreover, inhaled AONs are metabolized mostly in the lung , therefore limiting systemic exposure . Their clinical utility in lung diseases was illustrated in a recent study where inhaled AONs were used to inhibit the allergen-induced inflammation in asthmatic subjects . We hypothesized that inhaled AONs against selected PDE subtypes, by downregulating the expression of their targets locally, would reduce inflammation associated with cigarette smoke exposure. We reasoned that a combination of AONs against PDE4 and PDE7 subtypes would mediate improved pharmacological activity as compared to PDE4 only inhibitors. This study therefore examined the in vitro and in vivo potency of a combination of phosphorothioate AONs directed against PDE4B/4D and PDE7A subtypes. These AONs incorporate 2'-deoxy-2'-Fluoro-β-D-Arabinonucleic Acid (FANA) modifications, which have been shown to provide increased potency and increased stability as compared to second generation phosphorothioate oligonucleotides [48, 49].
Antisense oligonucleotides (AON)
AONs were obtained from the University of Calgary DNA Synthesis Laboratory (UCDNA) and were purified by anion-exchange HPLC. AON sequences were as follows (lowercase: DNA; bold uppercase: FANA; all with phosphorothioate linkages): human PDE4B/4D (5'-TCtgcccatgtctCCCA-3'); human PDE7A (5'-TCATgagtggcagctgcAATT-3'); mouse PDE4B/4D (5'-GGttgctcaggtctgcACAG-3'); mouse PDE7A (5'-TCCAGatcgtgaGTGGC-3'). Control sequences with mismatched nucleotides were as follows: for human PDE4B/4D (5'-AGacgggtacagaGGGT-3'); human PDE7A (5'-AGTActcaccgtcgacgTTAA-3'); mouse PDE4B/4D (5'-GCatggtctgcagtggACTC-3'); mouse PDE7A (5'-TGCTCaacgtctGAGGG-3').
Cell culture and transfection
Normal human bronchial epithelial cells (NHBE) were cultured in antibiotic-free BEGM medium (Clontech) until 70–90% confluency was reached, and were then transfected for 24 h with the AONs using Lipofectamine 2000 (Invitrogen). Fresh media containing TNF-α, IL-1β and IFN-γ (10 ng/ml each; Peprotech) was added 4 h before the end of the transfection.
Mouse models of cigarette smoke-induced lung inflammation. 1-week smoke model
The housing and care of mice (male C57Bl/6, Charles Rivers Laboratory) used in this study were provided according to protocols approved by Mispro Biotech's Institutional Animal Care and Use Committee, in conformity with Canadian Council on Animal Care (CCAC) guidelines. On days 1, 3, 6 and 8, groups of mice were anesthesized with ketamine and xylazine (60 mg/kg and 12 mg/kg, i.p.) and intubated. Aerosols of vehicle (endotoxin-free distilled water), AONs or controls were administered into the trachea using a microsprayer (Penn-Century). On days 6 to 9, other groups of mice were treated by gavage with vehicle (0.5% methylcellulose) or roflumilast (Rasayan). On days 6 to 9 (3 h after drug treatment), mice were nose-only exposed to the smoke of two 2R4f reference cigarettes (University of Kentucky) per day. Cigarette smoke was delivered to mice using a nose-only exposure system (Proto-Werx), at a rate of 1 puff (20 ml) per minute, as described previously [12, 50]. 2-week smoke model: On days 1, 2, 3, 4, 5, 8 and 15, groups of mice were treated with vehicle, AONs or controls as described above. On days 8 to 12 and 15 to 18, mice were nose-only exposed to the smoke of two 2R4f reference cigarettes (University of Kentucky) per day, as described above for the 1-week smoke model. Mice were killed by anesthetic overdose (sodium pentobarbital 88 mg/kg i.p.) and exsanguination 20 h following the last smoke exposure. Bronchoalveolar lavage (BAL) were performed as described previously . Differential cell counts were determined on at least 300 cells using standard morphological criteria.
Real-time PCR primer sequences
Annealing Temperature (°C)
Cytokines and chemokines quantification
ELISA kits for human IL-8 (BD Biosciences), human monocyte chemoattractant protein-1 (MCP-1; R&D Systems), and murine KC (R&D Systems) were used. Mouse pro-MMP-9 was quantified using the SearchLight array testing service (Thermo Fisher Scientific).
Results are expressed as mean ± standard error to the mean (SEM). Statistical comparisons between groups were carried out using unpaired t-test.
Target mRNA knock down by PDE 4B/4D and PDE 7A antisense oligonucleotides in human broncho-epithelial cells
AON sequences were designed to specifically target the mRNA for human PDE4B/4D and synthesized with a phosphorothioate backbone. The high sequence homology between the catalytic domains of PDE4B and PDE4D genes enabled the design of single AON sequences specific for both isotypes. Phosphorothioate AON sequences were also designed to specifically target the mRNA for human PDE7A. Following screening for inhibition of target mRNA expression in 293 cells and in A549 cell lines, lead AON sequences were characterized by dose-response and time course analysis. For the most potent AONs, chemistry optimisation was performed by including FANA substitutions in a gapmer configuration in order to improve efficacy and duration of action, as well as to improve resistance to nuclease degradation. From this screening, two AON sequences were selected for this study, and identified as AON 4B/4D and AON 7A. Base mismatched oligonucleotides were used as control sequences.
PDE4B/4D and 7A mRNA knock down by antisense oligonucleotides correlates with inhibition of inflammatory mediators production by human broncho-epithelial cells in vitro
Efficacy of locally administered PDE4B/4D and PDE7A AON against cigarette smoke-induced lung inflammation in mice, and comparison with roflumilast
We next wanted to determine whether inhibition of PDE4B, PDE4D and PDE7A expression in the lung would protect against lung inflammation in mice exposed to cigarette smoke. Mouse specific AONs were designed, screened for target knock down in murine cell lines, and chemically modified to include FANA substitutions. One lead sequence specific for both mouse PDE4B and 4D mRNAs (AON 4B/4D), and one for mouse PDE7A (AON 7A) were selected, as well as control sequences, and used for all in vivo experiments.
Sustained anti-inflammatory activity of PDE4B/4D and PDE7A AON following once a week treatment in cigarette smoke-exposed mice
Much interest in the field of COPD has focused on strategies aimed at reducing the underlying inflammation through broad inhibition of the PDE4 isoforms. Orally administered second generation PDE4 inhibitors, such as cilomilast and roflumilast, have undergone extensive investigation and are currently in Phase III clinical development. Although effective, dose-limiting side effects related to the systemic exposure of these drugs have hampered their clinical development. Therefore, there is still a need for more selective and/or more potent PDE inhibitors with improved therapeutic ratios.
Increased interest in the therapeutic use of AONs has been fueled by recent pre-clinical [38, 44, 53, 54, 55] and clinical studies  showing their potential benefit in respiratory disorders involving inflammation such as asthma. We have developed FANA-modified antisenses oligonucleotides specifically targeting PDE isotypes 4B, 4D and 7A, as a potential new inhaled drug for the treatment of COPD. In NHBE cells, high levels of PDE4B, 4D and 7A mRNA inhibition were correlated with reduced functional activity, as illustrated by dose-dependent inhibition of IL-8 and MCP-1 secretion. The potency of combined PDE4B/4D and 7A AON on inflammatory markers in vitro is in line with their protective effect in vivo, as evidenced by their ability to reduce the smoke-induced recruitment of neutrophils and secretion of KC and MMP-9 in mice. Inhibition of neutrophil recruitment was also associated with PDE mRNA inhibition in vivo. Interestingly, we observed that the dose required to achieve significant inhibition of the three PDE targets at the mRNA level (0.2 mg/kg/day) was the same as the dose required to block the recruitment of neutrophils, KC and pro-MMP-9. At lower doses where only PDE4B mRNA inhibition was measured, no reduction in neutrophil recruitment was observed (see Figures 4A and 5A). Because PDE4B, 4D and 7A are expressed to different levels in different cell types, these data do not allow us to determine in which cellular subset in the BAL fluid the inhibition of PDE mRNA was the most efficient. The fact that total RNA from the mixed cell populations present in the BAL was measured might reflect this limitation. Nevertheless, these results are consistent with the idea that downregulating different PDE subtypes in different cell populations which together orchestrate the inflammatory response is required to achieve a protective effect against neutrophils in vivo. Moreover, and as previously shown in PDE4B and PDE4D knock out mice , these data support the idea that different PDE isotypes play complementary roles in the control of inflammatory cell recruitment. In the acute smoke exposure protocol used here (1-week model), orally delivered roflumilast at 5 mg/kg/day partially reduced neutrophil recruitment (20% reduction), but statistical significance could not be reached, and had no effect on KC or pro-MMP-9 secretion (Figure 6). Martorana et al. reported that oral roflumilast at 5 mg/kg inhibited neutrophils by 30% following one acute (20 minutes) exposure to cigarette smoke . The longer smoke exposure period used here might explain the difference between the studies. Yet, the greater efficacy of the combined AONs PDE4B/4D and PDE7A supports the hypothesis that the anti-inflammatory activity of PDE4 inhibitors might benefit from the addition of a PDE7 inhibitor.
Besides neutrophils, lung macrophages are believed to play an important role in COPD, in part by their ability to release TNF-α, which can drive neutrophil influx and activate MMP-12 release, leading to extracellular matrix degradation . In both the 1-week and the 2-week smoke models used here, macrophages were significantly increased in lung lavages upon smoke exposure. However, no reduction in macrophage counts were observed in mice treated with PDE4B/4D and 7A AONs, nor with roflumilast (data not shown). Although roflumilast has been shown to reduce macrophage density in lung tissue of mice chronically exposed to smoke (7 months), no effect of roflumilast on macrophages was seen following acute smoke exposure in that study , which is in line with our results. Thus, lack of efficacy on macrophages in the acute smoke exposure protocols used here may reflect the limitations of the acute model, and therefore may not be predictive of the outcome in chronic smoke exposure regimens.
When tested in a two-week smoke exposure protocol, combined PDE4B/4D and 7A AONs (at 0.05 mg/kg/day) were found to significantly reduce neutrophil influx, as well as KC and pro-MMP-9 in lung lavages collected four days after the last AONs treatment (Figure 7). In addition, treatment with combined PDE4B/4D and 7A AONs also resulted in significant inhibition of lymphocyte recruitment (data not shown). Results from these experiments suggest that once a steady state level of AONs is reached in the lung, a once-a-week treatment regimen could be sufficient to keep cellular inflammation to low levels. Although the results from this 2-week smoke exposure protocol are encouraging, more studies are needed to verify whether protection against inflammation is maintained in more chronic smoke exposure models, and whether PDE AON treatment can be beneficial on long term endpoints such as emphysema.
Delivery of AON directly to the lung via inhalation presents key advantages over systemic delivery of small molecule PDE4 inhibitors. Inhalation of AONs achieves appreciable local lung concentrations at the site of action, at lower administered doses. In a 14-day inhalation study in monkeys, PDE-targeting FANA AONs were found to be safe and well tolerated at all dose levels tested (from 0.05 to 2.5 mg/kg/day) . Moreover, pharmacokinetic studies indicated very low levels of AON in plasma (<1%), and no plasma accumulation was obtained after repeated doses. In humans, there were no detectable levels of AON in plasma following inhalation for four consecutive days of 1.5 mg of TPI ASM8, an AON drug candidate in development for the treatment of asthma .
Findings from the present study show for the first time that a multi-target AON-based approach directed against specific PDE isoforms is effective at reducing key inflammatory markers characterizing COPD. While others have begun to explore the concept that combined or dual PDE4/PDE7 inhibitors may provide a better therapeutic ratio , our data support this idea and suggest that such an approach is valuable for potent inhibition of key inflammatory markers. Together, the potential favorable safety profile of locally delivered AON, combined with the improved efficacy resulting from direct access to target cells in the lung, support further development of PDE AON for chronic respiratory indications such as COPD and asthma.
The authors are grateful to Dr. Mark Parry-Billings for critical reading of the manuscript.
- 22.Kuss H, Hoefgen N, Johanssen S, Kronbach TCR: In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12–281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther 2003, 307:373–385.CrossRefPubMedGoogle Scholar
- 28.Dietsch GN, DiPalma CR, Eyre RJ, Pham TQ, Poole KM, Pefaur NB, Welch WD, Trueblood E, Kerns WD, Kanaly ST: Characterization of the Inflammatory Response to a Highly Selective PDE4 Inhibitor in the Rat and the Identification of Biomarkers that Correlate with Toxicity. Toxicologic Pathology 2006, 34:39–51.CrossRefPubMedGoogle Scholar
- 30.Chapman RW, House A, Jones H, Richard J, Celly C, Prelusky D, Ting P, Hunter JC, Lamca J, Phillips JE: Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats. Eur J Pharmacol 2007, 571:215–221.CrossRefPubMedGoogle Scholar
- 33.Robichaud A, Stamatiou PB, Jin C, Lachance N, MacDonald D, Laliberté F, Liu S, Huang C, Conti M, Chan CC: Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002, 110:1045–1052.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA: Discovery of BRL 50481 [3-(N, N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: In Vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes. Mol Pharmacol 2004, 66:1679–1689.CrossRefPubMedGoogle Scholar
- 39.Crosby JR, Guha M, Tung D, Miller DA, Bender B, Condon TP, York-DeFalco C, Geary RS, Monia BP, Karras JG, Gregory SA: Inhaled CD86 Antisense Oligonucleotide Suppresses Pulmonary Inflammation and Airway Hyper-responsiveness in Allergic Mice. J Pharmacol Exp Ther 2007, 321:938–946.CrossRefPubMedGoogle Scholar
- 43.Bhindi R, Fahmy RG, Lowe HC, Chesterman CN, Dass CR, Cairns MJ, Saravolac EG, Sun L-Q, Khachigian LM: Brothers in Arms: DNA Enzymes, Short Interfering RNA, and the Emerging Wave of Small-Molecule Nucleic Acid-Based Gene-Silencing Strategies. Am J Pathol 2007, 171:1079–1088.CrossRefPubMedPubMedCentralGoogle Scholar
- 47.Gauvreau GM, Boulet LP, Cockcroft DW, Baatjes A, Cote J, Deschesnes F, Davis B, Strinich T, Howie K, Duong M, Watson RM, Renzi PM, O'Byrne PM: Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008, 177:952–958.CrossRefPubMedGoogle Scholar
- 48.Damha MJ, Noronha AM, Wilds CJ, Trempe JF, Denisov A, Gehring K, Pon RT: Properties of arabinonucleic acids (ANA & 20'F-ANA): implications for the design of antisense therapeutics that invoke RNase H cleavage of RNA. Nucleosides Nucleotides Nucleic Acids 2001, 20:429–440.CrossRefPubMedGoogle Scholar
- 49.Ferrari N, Bergeron D, Tedeschi A-L, Mangos MM, Paquet L, Renzi PM, Damha MJ: Characterization of Antisense Oligonucleotides Comprising 2'-Deoxy-2'-Fluoro-beta-D-Arabinonucleic Acid (FANA): Specificity, Potency, and Duration of Activity. Ann NY Acad Sci 2006, 1082:91–102.CrossRefPubMedGoogle Scholar
- 54.Allakhverdi Z, Allam M, Renzi PM: Inhibition of Antigen-induced Eosinophilia and Airway Hyperresponsiveness by Antisense Oligonucleotides Directed against the Common beta Chain of IL-3, IL-5, GM-CSF Receptors in a Rat Model of Allergic Asthma. Am J Respir Crit Care Med. 2002,165(7):1015–1021.CrossRefPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.